Acute respiratory failure after interferon-γ therapy of end-stage pulmonary fibrosis

被引:59
作者
Honoré, I
Nunes, H
Groussard, O
Kambouchner, M
Chambellan, A
Aubier, M
Valeyre, D
Crestani, B
机构
[1] Hop Bichat, Serv Pneumol, F-75877 Paris 18, France
[2] Hop Bichat, INSERM, U408, F-75877 Paris, France
[3] Hop Beaujon, Serv Anat Pathol, Clichy, France
[4] Hop Avicenne, Serv Anat Pathol, Bobigny, France
[5] Assistance Publ Hop Paris, Paris, France
[6] Hop Avicenne, Serv Pneumol, F-93009 Bobigny, France
[7] Hop Avicenne, EA 2363, F-93009 Bobigny, France
关键词
drug toxicity; lung diseases; interstitial; interferon type II;
D O I
10.1164/rccm.200208-818CR
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Interferon (IFN)-gamma was recently proposed as a treatment for idiopathic pulmonary fibrosis. We report on four patients who developed acute respiratory failure with new alveolar opacities after 2 (two patients), 6, and 35 injections of IFN-gamma-1b. All four patients had advanced idiopathic pulmonary fibrosis (total lung capacity less than 45% predicted or carbon monoxide diffusion capacity less than 30% predicted), and two patients had familial pulmonary fibrosis. No other cause of deterioration was found. Refractory hypoxemia led to death in three cases and to lung transplantation in one case. Pathologic studies in two patients showed diffuse alveolar damage lesions with preexisting usual interstitial pneumonia. These cases suggest that IFN-gamma therapy can induce an acute respiratory failure in patients with end-stage idiopathic pulmonary fibrosis.
引用
收藏
页码:953 / 957
页数:5
相关论文
共 14 条
  • [1] CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis
    Akira, M
    Hamada, H
    Sakatani, M
    Kobayashi, C
    Nishioka, M
    Yamamoto, S
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1997, 168 (01) : 79 - 83
  • [2] American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, P646
  • [3] Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis
    Gudmundsson, G
    Hunninghake, GW
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (10) : 2386 - 2390
  • [4] MOLECULAR MECHANISMS OF ANTIFIBROTIC EFFECT OF INTERFERON-GAMMA IN BLEOMYCIN MOUSE MODEL OF LUNG FIBROSIS - DOWN-REGULATION OF TGF-BETA AND PROCOLLAGEN-I AND PROCOLLAGEN-III GENE-EXPRESSION
    GURUJEYALAKSHMI, G
    GIRI, SN
    [J]. EXPERIMENTAL LUNG RESEARCH, 1995, 21 (05) : 791 - 808
  • [5] HONORE I, 2002, REV MAL RESPIR, V195, P128
  • [6] ACUTE EXACERBATION IN IDIOPATHIC PULMONARY FIBROSIS - ANALYSIS OF CLINICAL AND PATHOLOGICAL FINDINGS IN 3 CASES
    KONDOH, Y
    TANIGUCHI, H
    KAWABATA, Y
    YOKOI, T
    SUZUKI, K
    TAKAGI, K
    [J]. CHEST, 1993, 103 (06) : 1808 - 1812
  • [7] RAGHU G, 2001, CHEST, V120, pS185
  • [8] A PHASE-I TRIAL OF RECOMBINANT INTERLEUKIN-2 COMBINED WITH RECOMBINANT INTERFERON-GAMMA IN PATIENTS WITH CANCER
    REDMAN, BG
    FLAHERTY, L
    CHOU, TH
    ALKATIB, A
    KRAUT, M
    MARTINO, S
    CHEN, B
    KAPLAN, J
    VALDIVIESO, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) : 1269 - 1276
  • [9] INDUCTION OF ANTINUCLEAR ANTIBODIES IN PATIENTS WITH RHEUMATOID-ARTHRITIS RECEIVING TREATMENT WITH HUMAN RECOMBINANT INTERFERON-GAMMA
    SEITZ, M
    FRANKE, M
    KIRCHNER, H
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1988, 47 (08) : 642 - 644
  • [10] PILOT-STUDY OF HUMAN RECOMBINANT INTERFERON-GAMMA AND ACCELERATED HYPERFRACTIONATED THORACIC RADIATION-THERAPY IN PATIENTS WITH UNRESECTABLE STAGE IIIA/B NONSMALL CELL LUNG-CANCER
    SHAW, EG
    DEMING, RL
    CREAGAN, ET
    NAIR, S
    SU, JQ
    LEVITT, R
    STEEN, PD
    WIESENFELD, M
    MAILLIARD, JA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (04): : 827 - 831